報價延遲最少15分鐘:2026/07/16 08:20 EDT
盤前時段
|
||||
|
5.29 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.29
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.31/-0.29
|
|
企業價值
316.44M
|
| 資產負債 |
|
每股賬面淨值
1.21
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
40.52M
|
|
每股收益
0.73
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification. |
